Holen Sie sich die Stockscreener-App
12.67
1.86%
-0.24
Handel nachbörslich:
12.70
0.03
+0.24%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MYGN?
Forum
Prognose
Aktiensplit
Myriad Genetics Inc Aktie (MYGN) Neueste Nachrichten
Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Sold by Nisa Investment Advisors LLC - Defense World
Piper Sandler Issues Pessimistic Forecast for Myriad Genetics (NASDAQ:MYGN) Stock Price - Defense World
Myriad Genetics (NASDAQ:MYGN) Price Target Cut to $18.00 by Analysts at The Goldman Sachs Group - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Price Target Cut to $14.00 by Analysts at Piper Sandler - MarketBeat
Fifth Third Bancorp Sells 23,296 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Revolutionary Prenatal Test Gives Parents Answers 2 Weeks Earlier Than Ever Before - StockTitan
DNA Diagnostics Market Booming Demand: Growth Trends, Share, - openPR
Cancer Diagnostics Market Top Companies StudyDanaher - openPR
(MYGN) Trading Advice - Stock Traders Daily
Myria and Beacher’s Madhouse to Bring an Unforgettable Spectacle to New Orleans During Big Game Weekend - GlobeNewswire Inc.
Why Is Larry Robbins Bullish on Myriad Genetics, Inc. (MYGN) Now? - Yahoo Finance
MYGN Stock Gains Following the Launch of Know More Sooner - MSN
Myriad Genetics (NASDAQ:MYGN) Reaches New 12-Month LowHere's Why - MarketBeat
FY2024 EPS Forecast for Myriad Genetics Increased by Analyst - Defense World
Myriad Genetics stock hits 52-week low at $12.16 amid market challenges - Investing.com
Myriad Genetics Introduces Online Prenatal Genetic Testing Resource - Yahoo Finance
FY2024 EPS Estimates for Myriad Genetics Raised by Analyst - MarketBeat
Predictive Genetic Testing and Consumer Genomics Market Research 2024-2034: Expanding DTC Genetic Testing, Consumer Interest in Personalized Healthcare, Awareness of Early Detection and Prevention - Yahoo Finance
Genomic Biomarker Market Growth in Future Scope 2025-2032 | - openPR
Myriad Genetics Doubles Cancer Testing Rates with Revolutionary Online Screening Tool - StockTitan
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology - Yahoo Finance
Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage - MSN
Myriad Genetics (NASDAQ:MYGN) Updates FY 2024 Earnings Guidance - MarketBeat
Stephens Reaffirms Equal Weight Rating for Myriad Genetics (NASDAQ:MYGN) - MarketBeat
Myriad Genetics stock hits 52-week low at $12.85 amid market challenges - Investing.com Australia
RSI Alert: Myriad Genetics (MYGN) Now Oversold - Nasdaq
Myriad Genetics: Navigating Through A Setback (NASDAQ:MYGN) - Seeking Alpha
Brokerages Set Myriad Genetics, Inc. (NASDAQ:MYGN) Target Price at $24.27 - MarketBeat
Myriad Genetics, Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full-Year Ended December 31, 2024 and Full-Year of 2025 - Marketscreener.com
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Rating of “Hold” from Analysts - Defense World
Myriad Genetics sees FY24 adjusted EPS 14c-15c, consensus 13c - MSN
Myriad Genetics (NASDAQ:MYGN) Hits New 12-Month LowWhat's Next? - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Releases Q4 2024 Earnings Guidance - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Issues FY 2025 Earnings Guidance - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Releases Q4 Earnings Guidance - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Releases FY25 Earnings Guidance - MarketBeat
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance - The Manila Times
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial ... - The Bakersfield Californian
Myriad Genetics (NASDAQ:MYGN) Stock Price Down 6%Here's What Happened - MarketBeat
Myriad Genetics and MD Anderson partner to evaluate molecular residual disease assay - MSN
Relationship Genetic Tests Market Report 2024, Featuring - GlobeNewswire
Relationship Genetic Tests Market Report 2024, Featuring Profiles of Laboratory Corporation of America, Quest Diagnostics, Cleveland Clinic, Myriad Genetics, Invitae and More - Yahoo Finance
Myriad Genetics FY2024 EPS Estimate Increased by Scotiabank - MarketBeat
Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Acquired by Nordea Investment Management AB - MarketBeat
MYGN Stock Gains Following Collaboration With Hannah Storm - Yahoo Finance
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History - The Manila Times
Myriad Genetics (NASDAQ:MYGN) Rating Increased to Buy at StockNews.com - MarketBeat
Myriad Genetics Partners with ESPN's Hannah Storm to Champion Breast Cancer Risk Testing - StockTitan
PARP Inhibitor Biomarkers Market Review 2024 and Forecast 2025-2035: Breast Cancer Applications Lead in Revenue, While Ovarian Cancer Emerges as the Fastest-Growing Opportunity - Yahoo Finance UK
Myriad Genetics and MD Anderson Launch Strategic Partnership to Advance MRD Assays - Zenopa
0.69%
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):